AI and liquid biopsy technologies are transforming cancer detection, diagnosis, and treatment planning. Advanced AI algorithms are now capable of analyzing biopsy slides to identify microscopic tumor features that may be overlooked by human pathologists. For example, the DeepHRD tool evaluates standard slides to detect specific genetic deficiencies, guiding personalized treatment decisions. AI is also improving medical image interpretation, analyzing PET/CT scans with greater speed and accuracy to identify subtle early signs of lymphoma and other cancers.
Beyond images, AI can process vast patient datasets, integrating genetic information, clinical records, and laboratory results to predict cancer risk, optimize therapy, and highlight potential drug targets.
Liquid biopsies complement these AI advances by detecting circulating tumor DNA (ctDNA) in blood. New whole-genome sequencing techniques with error correction enhance sensitivity, potentially enabling routine, non-invasive early cancer screening. Together, these technologies promise more accurate, cost-effective, and population-wide cancer detection and monitoring.